Tumor protein D52 is upregulated in oral squamous carcinoma cells under hypoxia in a hypoxia-inducible-factor-independent manner and is involved in cell death resistance.
Autophagy
HIF
Hypoxia
RNA stability
Squamous cell carcinoma
TPD52
Journal
Cell & bioscience
ISSN: 2045-3701
Titre abrégé: Cell Biosci
Pays: England
ID NLM: 101561195
Informations de publication
Date de publication:
03 Jul 2021
03 Jul 2021
Historique:
received:
13
04
2021
accepted:
18
06
2021
entrez:
4
7
2021
pubmed:
5
7
2021
medline:
5
7
2021
Statut:
epublish
Résumé
Tumor protein D52 (TPD52) reportedly plays an important role in the proliferation and metastasis of various cancer cells, including oral squamous cell carcinoma (OSCC) cells, and is expressed strongly at the center of the tumor, where the microenvironment is hypoxic. Thus, the present study investigated the roles of TPD52 in the survival and death of OSCC cells under hypoxia, and the relationship with hypoxia-inducible factor (HIF). We examined the expression of TPD52 in OSCC cells under hypoxic conditions and analyzed the effects of HIF on the modulation of TPD52 expression. Finally, the combinational effects of TPD52 knockdown and HIF inhibition were investigated both in vitro and in vivo. The mRNA and protein levels of TPD52 increased in OSCC cells under hypoxia. However, the increase was independent of HIF transcription. Importantly, the observation was due to upregulation of mRNA stability by binding of mRNA to T-cell intercellular antigen (TIA) 1 and TIA-related protein (TIAR). Simultaneous knockdown of TPD52 and inhibition of HIF significantly reduced cell viability. In addition, the in vivo tumor-xenograft experiments showed that TPD52 acts as an autophagy inhibitor caused by a decrease in p62. This study showed that the expression of TPD52 increases in OSCC cells under hypoxia in a HIF-independent manner and plays an important role in the proliferation and survival of the cells in concordance with HIF, suggesting that novel cancer therapeutics might be led by TPD52 suppression.
Sections du résumé
BACKGROUND
BACKGROUND
Tumor protein D52 (TPD52) reportedly plays an important role in the proliferation and metastasis of various cancer cells, including oral squamous cell carcinoma (OSCC) cells, and is expressed strongly at the center of the tumor, where the microenvironment is hypoxic. Thus, the present study investigated the roles of TPD52 in the survival and death of OSCC cells under hypoxia, and the relationship with hypoxia-inducible factor (HIF). We examined the expression of TPD52 in OSCC cells under hypoxic conditions and analyzed the effects of HIF on the modulation of TPD52 expression. Finally, the combinational effects of TPD52 knockdown and HIF inhibition were investigated both in vitro and in vivo.
RESULTS
RESULTS
The mRNA and protein levels of TPD52 increased in OSCC cells under hypoxia. However, the increase was independent of HIF transcription. Importantly, the observation was due to upregulation of mRNA stability by binding of mRNA to T-cell intercellular antigen (TIA) 1 and TIA-related protein (TIAR). Simultaneous knockdown of TPD52 and inhibition of HIF significantly reduced cell viability. In addition, the in vivo tumor-xenograft experiments showed that TPD52 acts as an autophagy inhibitor caused by a decrease in p62.
CONCLUSIONS
CONCLUSIONS
This study showed that the expression of TPD52 increases in OSCC cells under hypoxia in a HIF-independent manner and plays an important role in the proliferation and survival of the cells in concordance with HIF, suggesting that novel cancer therapeutics might be led by TPD52 suppression.
Identifiants
pubmed: 34217360
doi: 10.1186/s13578-021-00634-0
pii: 10.1186/s13578-021-00634-0
pmc: PMC8255020
doi:
Types de publication
Journal Article
Langues
eng
Pagination
122Subventions
Organisme : Japan Society for the Promotion of Science
ID : 18K09798
Références
Biochim Biophys Acta. 1998 Nov 26;1443(1-2):155-68
pubmed: 9838088
Clin Biochem. 2008 Oct;41(14-15):1224-36
pubmed: 18710659
Cancer Res. 2004 Jun 1;64(11):3814-22
pubmed: 15172988
Cancer Res. 2001 Apr 1;61(7):2911-6
pubmed: 11306467
Nat Cell Biol. 2008 Nov;10(11):1324-32
pubmed: 18836437
Biochim Biophys Acta Mol Basis Dis. 2017 Apr;1863(4):884-895
pubmed: 28095315
Genomics. 1996 Aug 1;35(3):523-32
pubmed: 8812487
BMC Genomics. 2008 May 12;9:216
pubmed: 18474104
Science. 2001 Apr 20;292(5516):468-72
pubmed: 11292861
J Mol Cell Biol. 2010 Dec;2(6):345-56
pubmed: 20980400
J Zhejiang Univ Sci B. 2015 Jan;16(1):32-43
pubmed: 25559953
Trends Pharmacol Sci. 2012 Apr;33(4):207-14
pubmed: 22398146
Genes Chromosomes Cancer. 2008 Oct;47(10):873-83
pubmed: 18615678
Free Radic Res. 2006 Aug;40(8):847-56
pubmed: 17015263
Mol Cancer Res. 2007 Feb;5(2):133-44
pubmed: 17314271
Nucleic Acids Res. 2011 Feb;39(3):1117-30
pubmed: 21233170
Int J Oncol. 2017 May;50(5):1634-1646
pubmed: 28339026
Cancer Res. 1999 Nov 15;59(22):5830-5
pubmed: 10582706
Oncol Res. 2017 May 24;25(5):773-779
pubmed: 27983909
Nat Med. 2020 Oct;26(10):1519-1530
pubmed: 33020645
Leuk Res. 2006 Nov;30(11):1355-63
pubmed: 16620967
Adv Drug Deliv Rev. 2009 Jul 2;61(7-8):623-32
pubmed: 19409433
BMC Cancer. 2010 Sep 17;10:497
pubmed: 20846453
J Oral Pathol Med. 1989 Aug;18(7):391-5
pubmed: 2585303
Oncogene. 1996 Feb 15;12(4):741-51
pubmed: 8632896
Oncol Lett. 2020 Aug;20(2):1906-1914
pubmed: 32724434
Biochem J. 2017 May 4;474(10):1669-1687
pubmed: 28298474
Am J Cancer Res. 2017 May 01;7(5):1198-1212
pubmed: 28560067
Oncogene. 2002 Oct 17;21(47):7256-65
pubmed: 12370817
Int J Cancer. 2005 Dec 20;117(6):1049-54
pubmed: 15986428
Cytogenet Cell Genet. 1998;81(3-4):199-201
pubmed: 9730602
Am J Cancer Res. 2012;2(4):397-413
pubmed: 22860231
Biochem Biophys Res Commun. 2005 Aug 26;334(2):654-60
pubmed: 16011831
Biochem Biophys Res Commun. 2006 Jun 9;344(3):798-806
pubmed: 16631610
Oncotarget. 2016 Sep 20;7(38):62340-62351
pubmed: 27694690
Cancer Res. 1995 Jul 1;55(13):2896-903
pubmed: 7796418
Blood. 2012 Feb 23;119(8):1872-81
pubmed: 22210879
Mol Cell Biol. 1992 Dec;12(12):5447-54
pubmed: 1448077
Stem Cells. 2009 Jan;27(1):7-17
pubmed: 18832593
Nat Cell Biol. 2016 Apr;18(4):356-65
pubmed: 27027486
Cancer Res. 2004 Mar 1;64(5):1589-94
pubmed: 14996714
Intern Med. 2002 Feb;41(2):79-83
pubmed: 11868612
Oncogene. 1998 Feb 19;16(7):873-81
pubmed: 9484778
Microsc Microanal. 2013 Jun;19(3):617-28
pubmed: 23552615
Int J Androl. 2010 Jun 1;33(3):507-17
pubmed: 19392831